Stockreport

Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 [Yahoo! Finance]

Larimar Therapeutics, Inc.  (LRMR) 
PDF On March 20, 2026, Wedbush raised the price target on Larimar Therapeutics, Inc. (NASDAQ:LRMR) to $13 from $12 previously and maintained an Outperform rating. Wedbush s [Read more]